Benralizumab did not meet its primary outcome in frequent-exacerbation COPD
Participants on benralizumab 100 mg had 2.04 moderate or severe COPD exacerbations per participant-year up to Week 56 versus 2.46 on placebo, a rate ratio of 0.83 (95% confidence interval 0.66 to 1.05), the record shows. The Fasenra label lists asthma, EGPA and HES; COPD is not an indication.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
Participants on benralizumab 100 mg had an annualized rate of 2.04 moderate or severe COPD exacerbations per participant-year up to Week 56, versus 2.46 for participants on placebo, a rate ratio of 0.83 with a 95% confidence interval of 0.66 to 1.05, the study record shows. In each of the record's two primary analyses, one in participants with ≥3 exacerbations in the previous year and one in the full analysis set with ≥2, the confidence interval for the rate ratio crosses 1, so the add-on drug did not meet its primary outcome in the study's superiority testing, the record shows. The Fasenra label lists add-on maintenance treatment of severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome without an identifiable non-hematologic secondary cause, and chronic obstructive pulmonary disease is not on the list of its indications (the label states).
Why it matters
The Fasenra label carries three listed indications: add-on maintenance treatment of severe asthma with an eosinophilic phenotype in patients aged 6 years and older, treatment of eosinophilic granulomatosis with polyangiitis in adults, and treatment of patients aged 12 years and older with hypereosinophilic syndrome without an identifiable non-hematologic secondary cause, the label states. The record describes RESOLUTE as a Phase 3 study of benralizumab 100 mg in patients with moderate to very severe COPD, a history of frequent COPD exacerbations and peripheral blood eosinophils ≥300/μL. Inclusion required ≥2 moderate or severe exacerbations in the previous year while on triple (ICS/LABA/LAMA) background therapy, so every participant was on inhaled triple treatment when randomized to benralizumab or placebo as an add-on, the record shows. The posted results add the Week 56 exacerbation rates, the key secondary outcomes and the safety counts for the two exacerbation-history analysis populations.
Exacerbation rates up to Week 56
The study record lists results first posted on November 20, 2026. The study started on August 26, 2019 and completed primary data collection on July 28, 2025, the record states.
- Primary analysis, participants with ≥3 exacerbations in the previous year (241 on benralizumab, 249 on placebo): 2.04 (95% confidence interval 1.69 to 2.46) versus 2.46 (95% confidence interval 2.05 to 2.95) exacerbations per participant-year; rate ratio 0.83 (95% confidence interval 0.66 to 1.05), p=0.1172, negative binomial model, the record shows.
- Primary analysis, full analysis set with ≥2 exacerbations in the previous year (331 on benralizumab, 345 on placebo): 1.86 (95% confidence interval 1.58 to 2.20) versus 2.05 (95% confidence interval 1.75 to 2.41); rate ratio 0.91 (95% confidence interval 0.74 to 1.11), p=0.3367.
- Key secondary outcome, annualized rate of severe exacerbations in the ≥3 analysis: 0.37 (95% confidence interval 0.28 to 0.49) versus 0.39 (95% confidence interval 0.30 to 0.52); rate ratio 0.95 (95% confidence interval 0.67 to 1.35), p=0.7644.
- Key secondary outcome, SGRQ total score change from baseline at Week 56 in the ≥3 analysis: -7.06 versus -4.95; difference in least squares means -2.092 (95% confidence interval -5.072 to 0.889), p=0.1686.
- Time to the first moderate or severe exacerbation in the ≥3 analysis: median 31.7 weeks (95% confidence interval 24.1 to 40.4) versus 26.1 weeks (95% confidence interval 21.1 to 31.1); hazard ratio 0.82 (95% confidence interval 0.66 to 1.03), p=0.1331.
- Mortality through up to 296 weeks in the ≥3 analysis: all-cause 3.00 versus 5.05 and respiratory-related 1.80 versus 2.32, in deaths per 100 participant-year, the record lists.
Study treatment and participants
RESOLUTE randomized 689 participants; 13 were removed from analyses for GCP non-compliance before unblinding, leaving 676 in the double-blind treatment period, 331 on benralizumab 100 mg and 345 on placebo, the record shows. Each arm received subcutaneous injections every 4 weeks for the first 3 doses, then every 8 weeks, and all participants were maintained on triple (ICS/LABA/LAMA) background therapy from enrollment throughout the treatment period.
Inclusion required age 40 to 85 years, a tobacco history of ≥10 pack-years, post-bronchodilator FEV1/FVC <0.70 with FEV1 ≤65% of predicted normal value, a blood eosinophil count ≥300/μL at screening, and a CAT total score ≥15, the record states. At Week 56, 289 of the benralizumab participants and 306 of the placebo participants completed Week 56; through the end of treatment, 226 and 218 completed, the record lists.
Safety events
In the safety analysis set, 155 of 331 benralizumab participants and 186 of 345 placebo participants had a serious adverse event, the record shows. Total deaths in the safety analysis set were 28 of 331 on benralizumab and 34 of 345 on placebo, the record lists. Adverse events were collected from the first dose to the last date in study, the record states.
What remains uncertain
The record posts no value for the placebo arm's median time to a first severe COPD exacerbation in the ≥2-exacerbation analysis; it lists 255.0 weeks (95% confidence interval 190.0 to not evaluable) for benralizumab and marks the placebo median not evaluable. (the study record)